"Organometallic Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)
| Descriptor ID |
D009942
|
| MeSH Number(s) |
D02.691
|
| Concept/Terms |
Organometallic Compounds- Organometallic Compounds
- Compounds, Organometallic
- Metallo-Organic Compounds
- Compounds, Metallo-Organic
- Metallo Organic Compounds
- Metalloorganic Compounds
- Compounds, Metalloorganic
|
Below are MeSH descriptors whose meaning is more general than "Organometallic Compounds".
Below are MeSH descriptors whose meaning is more specific than "Organometallic Compounds".
This graph shows the total number of publications written about "Organometallic Compounds" by people in this website by year, and whether "Organometallic Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 1 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 2 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 3 | 0 | 3 |
| 2009 | 4 | 1 | 5 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 3 | 1 | 4 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 2 | 5 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 1 | 3 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Organometallic Compounds" by people in Profiles.
-
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29; 403(10446):2807-2817.
-
Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Sci Rep. 2024 04 18; 14(1):8986.
-
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2024 02 16; 30(4):680-686.
-
A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran. Helicobacter. 2024 Jan-Feb; 29(1):e13061.
-
A radiomic- and dosiomic-based machine learning regression model for pretreatment planning in 177 Lu-DOTATATE therapy. Med Phys. 2023 Nov; 50(11):7222-7235.
-
Heterogeneous Head and Neck Paraganglioma With Distinct Features on 123 I-MIBG and 68 Ga-DOTATATE Images. Clin Nucl Med. 2022 Sep 01; 47(9):813-814.
-
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. JAMA Netw Open. 2022 01 04; 5(1):e2144170.
-
MRA of the Supraaortic Vasculature: Comparison of Gadobutrol and Gadoterate Meglumine at 1.5 T. J Magn Reson Imaging. 2022 08; 56(2):440-449.
-
177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 12; 22(12):1752-1763.
-
DOTATATE -Avid Bilateral Axilla and Subpectoral Lymphadenopathy Induced From COVID-19 mRNA Vaccination Visualized on PET/CT. Clin Nucl Med. 2021 Nov 01; 46(11):931-932.